MODERN CHI MED (01643) announced that the Group expects to achieve a profit attributable to equity holders of the Company of not less than RMB 2 million for the six months ended June 30, 2025, compared to a loss of approximately RMB 6.9 million for the six months ended June 30, 2024. The Board believes the turnaround from loss to profit is primarily due to a significant reduction in losses from disposal of property, plant and equipment. For the six months ended June 30, 2024, the Group incurred substantial losses from disposal of property, plant and equipment due to the dismantling of pharmaceutical production workshops. Nevertheless, revenue for the current period is expected to decrease by 15% to 20% compared to the six months ended June 30, 2024. The Board attributes the revenue decline mainly to intense industry competition.
Comments